Braftovi (encorafenib) + Erbitux (cetuximab) — Highmark
metastatic colorectal cancer (mCRC)
Initial criteria
- age ≥ 18 years
- diagnosis of metastatic colorectal cancer (ICD-10: C18, C20)
- BRAF V600E mutation as detected by an FDA-approved test
- Braftovi is used in combination with cetuximab
- member has received prior therapy for colorectal cancer